The results of the clinical trials were generally characterized as summaries or press releases ver ffentlicht, So that the data rarely taken by colleagues under the microscope and are not exhausted Pfend. Some Ver describe Publications CH5424802 Clinical trials are available, and a clearer Power ON Estimation of the risks and benefits. For example, was p38a / b 67 657 selective inhibitor RWJ evaluated in a human model with the injection of small amounts of LPS. The inhibitor significantly suppressed the reaction of fever and partially blocked the increase in serum concentrations of cytokines such as TNFa31. A Similar study on a second inhibitor p38, BIRB 796 showed that phosphorylation of the transcription factor p38 activation was blocked substrate 2 in peripheral blood cells after LPS injection.32 Although LPS data clearly show that p38 may regulate cytokine responses in humans, is the relevance of RA and other rheumatic diseases uncertain.
BIRB 796 was also tested in a Phase Bafetinib 2 study in RA, although the available information is limited. The first clinical study of the efficacy of RA involved VX 745, which was tested in a controlled study of placebo embroidered on 44 patients. Among the patients in the treated group achieved 43% American College of Rheumatology 20 response compared with 17% for placebo, and the results were found to be statistically significant. Although the differences are not very large are drug exposure was Hepatotoxizit limited t. Other undefined gastrointestinal toxicity T was also observed in a significant percentage of patients. VX 702, another selective inhibitor of p38, was examined in a short-term study of the acute coronary syndrome. Although it is not reported in a survey, the inhibition of p38 in this single-dose study, in order to suppress the levels of C-reactive protein compared with placebo-treated patients.
The same compound was also evaluated in a Phase 2 study in RA, known VERA study. It was a prospective study against placebo, embroidered Lee 315 patients in Eastern Europe, of which 278 completed 12 weeks of treatment. Since Lebertoxizit t with other inhibitors of p38 was observed, concomitant treatment with methotrexate has not authorized. Although data are limited, seems VX 702, a dose–Dependent, statistically significant increase in ACR 20 responder offer. Overall, the response was not robust, at a rate of 44% ACR 20 response compared with 31% for placebo. The h Most common adverse events were rash, infections and gastrointestinal Incompatible Possibility.
Information about Hepatotoxizit is t limited, but apparently there was no significant increase in patients with a triple Erh Hung or more liver enzymes in the treatment group. The compound is not used in combination with methotrexate, the effect on the liver function and to determine whether this approach is more effective than the use of the compound to be evaluated as a monotherapy. Safety device study and a Phase 1 clinical trial for efficacy in Phase 2 RA were using the p38 inhibitor SCIO 469th W While information on the efficacy in RA is limited, the company recorded a randomized controlled EEA, with 263 patients who had a toothache. The rationale for this study covers many pr Clinical data show that p38 in spinal nociception modules relates that intrathecal administration of p38 inhibitors significantly suppressed acute and chronic pain.